Viral escape from AAV expressed transgenes

$691,130P01FY2013AINIH

Scripps Florida, Jupiter FL

Investigators

Linked publications, trials & patents

Paper 39137042 Paper 38713520 Paper 37759764 Paper 37149081 Paper 37141171 Paper 36258013 Paper 36184851 Paper 35322228 Paper 34226687 Paper 34182803 Paper 33782545 Paper 33558455 Paper 33393506 Paper 32405514 Paper 32256496 Paper 31890736 Paper 31843447 Paper 31341061 Paper 31273195 Paper 31072208 Paper 30850342 Paper 30783968 Paper 30704961 Paper 30102296 Paper 29766031 Paper 29766023 Paper 29596011 Paper 29593050 Paper 29567311 Paper 29499946 Paper 29398483 Paper 29379011 Paper 29024785 Paper 28726259 Paper 28679752 Paper 28679290 Paper 28628097 Paper 28488944 Paper 28462820 Paper 28422793 Paper 28230658 Paper 28194442 Paper 28106060 Paper 28067312 Paper 27995975 Paper 27805569 Paper 27334589 Paper 26607476 Paper 26444083 Paper 26248318 Paper 26086867 Paper 25900654 Paper 25707797 Paper 25632938 Paper 25604619 Paper 25485285 Paper 25227756 Paper 25091489 Paper 24390333 Paper 24386892 Paper 23686826 Paper 23686825 Paper 23667257 Paper 23408132 Paper 23408131 Paper 22875565 Paper 21807555 Paper 21697477 Paper 21613393 Patent 12467063 Patent 12454702 Patent 12390539 Patent 12371710 Patent 11882815 Patent 11739346 Patent 10975391 Patent 10626161

Abstract

The broad purpose of this program-project is to show that advances AAV-based gene therapy enable stable, long-term suppression of HIV-1 replication. Our immediate goal is to stably suppress an ongoing SHIV-infection in rhesus macaques, using specific combinations of antiviral proteins delivered by self-complementary AAV vectors. Any effective therapy for HIV-1 infection has to solve the problem of viral escape. This project addresses the problem of viral escape from a cocktail of antibodies iteratively, by rapidly identifying viral escape pathways and adjusting these cocktails so that these pathways are blocked. We are aided in this effort by a variant of CD4-Ig, fused to a 14-amino-acid peptide that closely mimics a high-affinity binding region of CCR5. This enhanced CD4-Ig (

View original record on NIH RePORTER →